Наталья Трушенко

Dr. Наталья Трушенко


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2022 in PULMONOLOGIYA
Verified
Journal Article
Closed access
PDF file
SASergey Avdeev
Sergey Avdeev
ZAZaurbek Aisanov
Zaurbek Aisanov
ABA. S. Belevskiy
A. S. Belevskiy
MIM. M. Ilkovich
M. M. Ilkovich
EKE. A. Kogan
E. A. Kogan
ESE. I. Shmelev
E. I. Shmelev
Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic fibrotic interstitial pneumonia with a progressive course and poor prognosis. The prevalence of IPF in the Russian Federation is about 8 – 12 cases per 100,000 population. The basic treatment of IPF is antifibrotic agents.Methodology. The target audience of these clinical recommendations are therapists, general practitioners, pulmonologists, pathologists, radiologists, and medical rehabilitation doctors. Each thesis-recommendation about diagnostic and therapeutic procedures has been scored according to the scale of classes of recommendations from 1 to 5 and A, B, C scale of the levels of evidence. Clinical recommendations also contain comments and explanations to the theses, algorithms for the diagnosis and treatment of idiopathic pulmonary fibrosis, and reference materials.Conclusion. The presented clinical guidelines cover current information about the etiology and pathogenesis, clinical manifestations, diagnosis, treatment, and prevention of idiopathic pulmonary fibrosis. These guidelines were approved by the Scientific and Practical Council of the Ministry of Health of the Russian Federation in 2021.

21 June 2020 in PULMONOLOGIYA
Verified
Journal Article
Open access
SASergey Avdeev
Sergey Avdeev
NTN. N. Tsareva
N. N. Tsareva
ZMZ. M. Merzhoeva
Z. M. Merzhoeva
НТНаталья Трушенко
Наталья Трушенко
AYAndrey Yaroshetskiy
Andrey Yaroshetskiy
Acute Respiratory failure (ARF) is the leading cause of death in patients with severe COVID-19, who have been admitted to the hospital. Tradition - ally, it has been believed that with severe pneumonia complicated by ARF, survival can improve with the use of early intubation and artificial lung ventilation (ALV) in patients. However, according to recently published studies, COVID-19 has a very high death rate among patients receiving ALV. In case of early (pre-life support) start of oxygen therapy and respiratory support in patients with COVID-19 the need for transfer to the intensive care unit, tracheal intubation and ALV decreases, and therefore the prognosis improves. This article presents practical guidelines for oxygen therapy and respiratory support at the pre-life support in patients with COVID-19 infection complicated by ARF.

8 February 2023 in Life
Verified
Journal Article
Open access
PDF file
НТНаталья Трушенко
Наталья Трушенко
OSOlga Alexandrovna Suvorova
Olga Alexandrovna Suvorova
EPEkaterina S. Pershina
Ekaterina S. Pershina
GNGalina Nekludova
Galina Nekludova
SCSvetlana Yurievna Chikina
Svetlana Yurievna Chikina
SASergey Avdeev
Sergey Avdeev
Hypersensitivity pneumonitis (HP) is an interstitial lung disease (ILD) resulting from an immune-mediated response in susceptible and sensitized individuals to a large variety of inhaled antigens. Chronic HP with a fibrotic phenotype is characterized by disease progression and a dismal prognosis. The aim of this study was to identify predictors of progression and mortality in patients with chronic HP in real clinical practice. Materials and methods: This retrospective, multicenter, observational study used data from a registry of 1355 patients with fibrosing ILDs. The study included 292 patients diagnosed with chronic HP based on the conclusion of a multidisciplinary discussion (MDD). Results: The patients were divided into groups with progressive (92 (30.3%) patients) and nonprogressive pulmonary fibrosis (200 (69.7%) patients). The most significant predictors of adverse outcomes were a DLco < 50% predicted, an SpO2 at the end of a six-minute walk test (6-MWT) < 85%, and a GAP score ≥ 4 points. Conclusion: Pulmonary fibrosis and a progressive fibrotic phenotype are common in patients with chronic HP. Early detection of the predictors of an adverse prognosis of chronic HP is necessary for the timely initiation of antifibrotic therapy.

26 October 2020 in Tuberculosis and Lung Diseases
Verified
Journal Article
Open access
PDF file
ABAndrei Evgen'evich Bautin
Andrei Evgen'evich Bautin
SASergey Avdeev
Sergey Avdeev
ASA. A. Seyliev
A. A. Seyliev
MSM. V. Shvechkova
M. V. Shvechkova
ZMZ. M. Merzhoeva
Z. M. Merzhoeva
ORO. A. Rozenberg
O. A. Rozenberg
The objective: to evaluate the effectiveness of inhaled surfactant therapy in the integrated treatment of severe COVID-19 pneumonia in a multicenter prospective clinical trial of surfactant-BL.Subjects and methods. 122 patients with severe COVID-19-associated pneumonia treated in two treatment centers were enrolled in the study. All of them received antiviral, anticoagulant and anti-inflammatory therapy. 56 patients also received inhalation therapy with surfactant-BL (OOO Biosurf, St. Petersburg, Russia) at a dose of 1 mg/kg 2-3 times a day. The remaining 66 patients received no surfactant-BL inhalation. When included into the study, all patients were divided into two groups based on severity of the condition at the time of inclusion: 62 people (Group I) needed oxygen inhalation through a face mask with the flow of 6-8 L/min for hypoxemia correction (27 received surfactant therapy and 35 did not); other 60 patients (Group II) required non-invasive respiratory support (constant positive airway pressure, non-invasive mechanical ventilation, high-flow oxygen therapy), of them 29 received surfactant therapy, while 31 patients did not.Results. In Group I, switching to invasive mechanical ventilation was required for 3/27 (11.1%) patients who received surfactant therapy, and 10/35 (28.6%) who received no surfactant therapy (p = 0.085); lethality made 3/27 (11.1%) and 9/35 (25.7%) (p = 0.131), respectively. In Group II, among those who received surfactant therapy, 5/29 (17.2%) were switched to invasive mechanical ventilation and 18/31 (58.1%) among those who did not receive it (p = 0.001); lethality made 5/29 (17.2%) and 18/31 (58.1%) (p = 0.001), respectively. In the pooled group of 122 patients with severe COVID-19-associated pneumonia, 8 (14.3%) of 56 patients who received surfactant died, and 27 (40.9%) of 66 died among those who did not receive it, (p = 0.001).Conclusion: Inhalation surfactant therapy can reduce the frequency of switching patients to mechanical ventilation and statistically significantly reduce lethality caused by severe pneumonia associated with SARS-CoV-2.

1 March 2021 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
DKDjuro Kosanovic
Djuro Kosanovic
AYAndrey Yaroshetskiy
Andrey Yaroshetskiy
NTNatalia A. Tsareva
Natalia A. Tsareva
ZMZamira M. Merzhoeva
Zamira M. Merzhoeva
НТНаталья Трушенко
Наталья Трушенко
SASergey Avdeev
Sergey Avdeev
• COVID-19 may be characterized by an abnormal coagulation process and microvascular thrombosis of the lung vasculature. • COVID-19 may also be linked with acute respiratory distress syndrome (ARDS) and acute cor pulmonale (ACP). • We confirmed the development of ACP in a patient suffering from COVID-19. • We treated our patient with systemic thrombolysis and this resulted in a marked improvement in hemodynamics. • In addition, there was a significant reduction in hypercapnia, alveolar dead space, and ventilatory ratio.

12 February 2025 in PULMONOLOGIYA
Verified
Journal Article
Open access
PDF file
SASergey Avdeev
Sergey Avdeev
ZAZaurbek Aisanov
Zaurbek Aisanov
АВА. А. Визель
А. А. Визель
IDIrina V. Demko
Irina V. Demko
MIM. M. Ilkovich
M. M. Ilkovich
ESE. I. Shmelev
E. I. Shmelev
Hypersensitivity pneumonitis (HP) is an inflammatory and/or fibrotic lung disease that occurs in response to repeated inhalation of broad-spectrum aerosol antigens. The prevalence of HP ranges from 0.3 to 0.9 cases per 100,000 population. The basis treatment of HP therapy includes glucocorticoids, immunosuppressants, and antifibrotic drugs. The target audience of these clinical recommendations are general practitioners, pulmonologists, pathologists, radiologists, and medical rehabilitation specialists. Methods. Each thesis-recommendation for diagnostic and therapeutic measures is evaluated on a scale of evidence reliability from 1 to 5 and a scale of the recommendation persuasiveness with the categories A, B, C. The guidelines also contain comments and explanations to these thesis-recommendations, algorithms for the diagnosis and treatment of idiopathic pulmonary fibrosis, and reference materials. Conclusion. The presented clinical guidelines cover current information about the etiology and pathogenesis, clinical manifestations, diagnosis, and treatment of hypersensitivity pneumonitis. These guidelines were approved by the Scientific and Practical Council of the Ministry of Health of the Russian Federation in 2023.